Obesity and mortality in men with locally advanced prostate cancer
dc.contributor.author | Efstathiou, Jason A. | en_US |
dc.contributor.author | Bae, Kyounghwa | en_US |
dc.contributor.author | Shipley, William U. | en_US |
dc.contributor.author | Hanks, Gerald E. | en_US |
dc.contributor.author | Pilepich, Miljenko V. | en_US |
dc.contributor.author | Sandler, Howard M. | en_US |
dc.contributor.author | Smith, Matthew R. | en_US |
dc.date.accessioned | 2008-01-04T20:06:03Z | |
dc.date.available | 2009-01-07T20:01:17Z | en_US |
dc.date.issued | 2007-12-15 | en_US |
dc.identifier.citation | Efstathiou, Jason A.; Bae, Kyounghwa; Shipley, William U.; Hanks, Gerald E.; Pilepich, Miljenko V.; Sandler, Howard M.; Smith, Matthew R. (2007). "Obesity and mortality in men with locally advanced prostate cancer." Cancer 110(12): 2691-2699. <http://hdl.handle.net/2027.42/57506> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/57506 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17999404&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. Greater body mass index (BMI) is associated with shorter time to prostate-specific antigen (PSA) failure following radical prostatectomy and radiation therapy (RT). Whether BMI is associated with prostate cancer-specific mortality (PCSM) was investigated in a large randomized trial of men treated with RT and androgen deprivation therapy (ADT) for locally advanced prostate cancer. METHODS. Between 1987 and 1992, 945 eligible men with locally advanced prostate cancer were enrolled in a phase 3 trial (RTOG 85-31) and randomized to RT and immediate goserelin or RT alone followed by goserelin at recurrence. Height and weight data were available at baseline for 788 (83%) subjects. Cox regression analyses were performed to evaluate the relations between BMI and all-cause mortality, PCSM, and nonprostate cancer mortality. Covariates included age, race, treatment arm, history of prostatectomy, nodal involvement, Gleason score, clinical stage, and BMI. RESULTS. The 5-year PCSM rate for men with BMI <25 kg/m 2 was 6.5%, compared with 13.1% and 12.2% in men with BMI ≥25 to <30 and BMI ≥30, respectively (Gray's P = .005). In multivariate analyses, greater BMI was significantly associated with higher PCSM (for BMI ≥25 to <30, hazard ratio [HR] 1.52, 95% confidence interval [CI], 1.02–2.27, P = .04; for BMI ≥30, HR 1.64, 95% CI, 1.01–2.66, P = .04). BMI was not associated with nonprostate cancer or all-cause mortality. CONCLUSIONS. Greater baseline BMI is independently associated with higher PCSM in men with locally advanced prostate cancer. Further studies are warranted to evaluate the mechanism(s) for increased cancer-specific mortality and to assess whether weight loss after prostate cancer diagnosis alters disease course. Cancer 2007. © 2007 American Cancer Society. | en_US |
dc.format.extent | 114522 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Obesity and mortality in men with locally advanced prostate cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, Pennsylvania | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, University of California Los Angeles School of Medicine, Los Angeles, California | en_US |
dc.contributor.affiliationother | Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts ; Fax: (617) 726-4899. ; Massachusetts General Hospital, Yawkey 7038, 55 Fruit St., Boston, MA 02114 | en_US |
dc.identifier.pmid | 17999404 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/57506/1/23093_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.23093 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.